What is Ovid Therapeutics Inc (OVID) stock price today?

Ovid Therapeutics Inc (OVID) currently trades at $2.69 per share. The stock has a market capitalization of $465.47M and a P/E ratio of —x.

Is OVID stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Ovid Therapeutics Inc has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Ovid Therapeutics Inc's revenue and earnings?

Ovid Therapeutics Inc has trailing twelve-month (TTM) revenue of $7.25M with profit margins of -240.10%. Earnings per share (EPS) is $-0.23.

Is OVID stock overvalued or undervalued?

Based on our DCF model, Ovid Therapeutics Inc's intrinsic value is $4.43, representing a margin of safety of 64.11%. The stock currently trades at a P/E of —x.

OVID

Ovid Therapeutics Inc

NASDAQ: OVID · HEALTHCARE · BIOTECHNOLOGY

$2.69

-0.37% today

Updated 2026-04-29

Market cap

$465.47M

P/E ratio

—

P/S ratio

64.19x

EPS (TTM)

$-0.23

Dividend yield

—

52W range

$0 – $3

Volume

3.4M

Market cap

$465.47M

P/E ratio

—

P/S ratio

64.19x

EPS (TTM)

$-0.23

Dividend yield

—

52W range

$0 – $3

Volume

3.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

8.0

Growth

5.0

Quality

C+

2.0

Profitability

6.7

Valuation

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$5.25

+95.17%

12-Month target

—

Intrinsic (DCF)

$4.43

Margin of safety

+64.11%

0 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 845.00% QoQ

+ 64.11% below intrinsic value

Risks

- Thin margins at -240.10%

- Negative free cash flow $-10.41M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$1.50M	$392000.00	$566000.00	$7.25M	$7.25M
Net income	$-51.41M	$-52.34M	$-26.43M	$-17.41M	$9.66M
EPS	—	—	—	—	$-0.23
Free cash flow	$-56.65M	$-45.92M	$-56.03M	$-38.33M	$-10.41M
Profit margin	-3,420.95%	-13,351.79%	-4,670.14%	-240.13%	-240.10%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-07	PAPADOPOULOS, STELIOS	Buy	17,578	$2.56
2026-04-07	FRIEDMAN, BART	Buy	8,789	$2.56
2026-04-07	FITZGERALD, KEVIN JOSEPH	Buy	17,578	$2.56

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
OVID	$465.47M	28	8.0	2.0	6.7	5.0	+64.11%	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Ovid Therapeutics Inc trades at $2.69. Our Smart Value Score of 28/100 indicates the stock is weak. TTM revenue stands at $7.25M. with profit margins at -240.10%. Our DCF model estimates intrinsic value at $4.43.

Frequently asked questions

What is Ovid Therapeutics Inc's stock price?

Ovid Therapeutics Inc (OVID) trades at $2.69.

Is Ovid Therapeutics Inc overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell). DCF value $4.43.

What is the price target of Ovid Therapeutics Inc (OVID)?

The analyst target price is $5.25, representing +95.2% upside from the current price of $2.69.

What is the intrinsic value of Ovid Therapeutics Inc (OVID)?

Based on our DCF model, intrinsic value is $4.43, a +64.1% margin of safety versus $2.69.

What is Ovid Therapeutics Inc's revenue?

TTM revenue is $7.25M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio64.19x

ROE-17.50%

Beta-0.03

50D MA$2.20

200D MA$1.54

Shares out0.17B

Float0.10B

Short ratio—

Avg volume3.4M

Performance

1 week+1.50%

1 month+27.96%

3 months+74.19%

YTD+65.64%

1 year—

3 years—

5 years—

Compare

OVID vs LLY →OVID vs JNJ →OVID vs ABBV →Stock screener →